Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Has anybody a serious argument against funding this.

Really pleased to have presented work on targeting GPR89 in breast cancer with @ricoferro.bsky.social from the Tutt and Lord labs as part of the ICRs Centre for Target Validation @icrlordlab.bsky.social at #Targets2025 in Boston @icr.ac.uk @breastcancernow.bsky.social

Ever wondered what S-phase tastes like? 3 lucky presenter prize winners will find out (+Amazon voucher!) at #ACDTM25. You can still register for this fantastic Melbourne meeting Oct 20-22. Official 10 year old taste tester: "lemon excision repair" is the best flavour www.australiancellcycle.org

Yes ! Drive and intelligence more important than experience.

PDTF - Homologous Recombination Defective Cancers ( Profs Chris Lord and Andrew Tutt) in Chelsea | The Institute of Cancer Research View details and apply for this PDTF - Homologous Recombination Defective Cancers ( Profs Chris Lord and Andrew Tutt) vacancy in Chelsea . Salary: Dependent on relevant Postdoctoral exp...

We're hiring ! Specifically....we are seeking to appoint a creative and motivated Postdoctoral Training Fellow to study how drug resistance emerges in homologous recombination defective (HRD) breast cancers and how this could be targeted. jobs.icr.ac.uk/vacancies/13...

A photo of Jim O'Neil getting sworn in by RFK Jr. You can see a close-up of his tie.

The same tie on Otaa's website. The site shows the tie is made from 100% microfiber.

The label for Otaa'a ties. It says "Designed in Australia."

The back of the label. It says "100% Microfiber. Hand Made Made in China"

RFK Jr. taps his top deputy, Jim O’Neill, to be the new CDC director. Both men appear to wear skinny ties from Otaa. Otaa's ties are made in China from microfiber, a kind of plastic that, under the right conditions, can migrate to your balls.

NASP modulates histone turnover to drive PARP inhibitor resistance - Nature PARP inhibitor treatment triggers histone release from the chromatin in cancer cells; consequently, targeting the histone chaperone NASP renders cells vulnerable to PARP inhibition.

Thrilled to share our latest work, just published in @nature.com ⬇
www.nature.com/articles/s41...

We discovered that PARP inhibitors 💊 trigger histone eviction from the chromatin and this creates a hidden vulnerability in PARPi resistant tumors.
🧵 (1/8)

our bit funded by @breastcancernow.bsky.social @cancerresearchuk.org and carried out @icr.ac.uk

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers Nature Communications - The RNA editing enzyme ADAR1 blocks interferon responses triggered by cytosolic RNA sensors, and has been proposed as a potential target in immuno-oncology. Here, the...

With super Roman Chabanon and Sophie Postal Vinay, we show that inhibition of RNA editor ADAR1 causes a new form of BRCA synthetic lethality>autocrine inferferon poisoning. Relevant for ADAR1 drug discovery. Could provide a mechanistically different approach than PARPi. rdcu.be/eyo6t

Academic writing is a craft. ✍️

You’re not born knowing how to write great papers, succinct emails, or convincing proposals. You get better by doing it badly, then better, then well.

Your writing is the first thing people see before they meet you. Make it count.

This is fascinating:

Watch this space: Stephen is going to do great things with this funding from the Lister Institute.

Incredibly humbled and honoured to have been awarded the 2025 Research Prize from @thelisterinstitute.bsky.social. ❤️

🧬 We’re harnessing high-resolution molecular profiling + AI to uncover how cancer disables the immune system and find ways of restoring it. @icr.ac.uk

#bcsm #ai #CancerResearch

🧬 Excited to announce the 2nd Euro Cancer DepMap Symposium bringing together leading minds in functional genomics, cancer vulnerabilities, AI, CRISPR and anti-cancer target discovery.📍Join us in Milan for cutting-edge science, open discussion & collaboration. #EuroDepMap #CancerResearch #CRISPR

YouTube video by Human Technopole 1st European Cancer Dependency Map Symposium

Following the success of the first European Cancer Dependency Map Symposium in 2023, we are excited to announce the 2nd edition, to be held at Human Technopole on the 20th November 2025. Registration and Poster submission now open!
humantechnopole.it/en/trainings...
youtu.be/x2erCuovGvc
#EuroDepMap

Loving “pertomics”. Going to push the term “buffomics” too.

UK unveils £1B plan to become leading cancer research hub just outside the Golden Triangle The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 billion ($1.3 billion) cancer research and manufacturing hub on the outskirts | ...

www.fiercebiotech.com/biotech/uk-u...

Scientific Operations Project Manager in Chelsea | The Institute of Cancer Research View details and apply for this Scientific Operations Project Manager vacancy in Chelsea . Salary : Commencement on the salary range is subject to comparable skills and experience. Future p...

We're looking for a Scientific Operations Project Manager
to join us at ICR, London. Role is aimed at establishing new funding streams, collaborations with biotech. and pharma and managing collaborations with other academic groups. jobs.icr.ac.uk/vacancies/11...

pubmed.ncbi.nlm.nih.gov/28535155/

The OptiTROP-Breast01 phase 3 trial evaluated sacituzumab tirumotecan (sac-TMT) versus chemotherapy in patients with heavily pretreated, locally recurrent or metastatic triple-negative #BreastCancer

www.nature.com/articles/s41...

✅Sac-TMT significantly improved progression-free survival PFS

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy - Nature The discovery that BRCA1/2 mutant cells (defective in the homologous recombination pathway of DNA repair) are spectacularly sensitive to inhibition of the enzyme PARP (involved in base excision repair...

showing true (!) synthetic lethality
www.nature.com/articles/nat... www.nature.com/articles/nat...

this week 20 years ago, Nature published two seminal papers showing for the first time that BRCA-mutant cells were selectively sensitive to PARP inhibitors, paving the way for clinical trials and approval of PARP inhibitors for patients with BRCA-mutant ovarian and breast cancers, and beyond.

Scientific Officer - Target Validation and DNA Damage Response Group (Prof Andrew Tutt) in Chelsea | The Institute of Cancer Research View details and apply for this Scientific Officer - Target Validation and DNA Damage Response Group (Prof Andrew Tutt) vacancy in Chelsea . Salary : Commencement on the salary range is s...

Interested in starting your cancer research career in London ?We're looking for a Scientific Officer to support our work on synthetic lethality in triple negative and BRCA1/2 mutant cancers. Ideal job for a new graduate who wants to kick start their research career. jobs.icr.ac.uk/vacancies/12...

And Elvis 75 the best single never released

A redefined InDel taxonomy provides insights into mutational signatures - Nature Genetics This paper describes a framework for classifying small insertions and deletions from genomic data and applies it to a large dataset comprising seven tumor types. The analysis highlights new insertion ...

PAPER OUT!! 🥳🎉💃🏻🕺🏻💃🏻🕺🏻

A redefined InDel taxonomy provides insights into mutational signatures @NatureGenet

Brainchild of the amazing #GeneKoh
(Sir Jeffrey Cheah ECR)

Tweetorial below!! 👇

1/n

www.nature.com/articles/s41...

New pill can slow progression of incurable breast cancer Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.

www.bbc.co.uk/news/article.... Excellent news for breast cancer patients, based on great work from ICR scientists including our own Nick Turner.

A must for all DNA repair aficionados!

Egmond DNA Repair Meeting → April 19–24, 2026 🇳🇱
✔️ Confirmed top speakers
✔️ Ample opportunities for talks & posters

Don’t miss it: dnarepairmeeting-egmond2026.com

We had the most fantastic joint lab retreat with our friends @josjonkers.bsky.social and Sabine Linn and their super smart colleagues @nkinl.bsky.social. The start of a lot of collaborative work targeting HRD and ILC.

Regulation of metastatic organotropism Metastasis is responsible for most cancer-related deaths. Different cancers have their own preferential sites of metastases, a phenomenon termed metastatic organotropism. The mechanisms underlying org...

Super nice review on metastasis organo-tropism⬇️ the process where tumor cells preferentially spread to specific distant organs, and represents a critical aspect of cancer biology with profound implications for patient outcomes. #CDH1
www.cell.com/trends/cance...

Impact of BRCA mutations, age, surgical indication, and hormone status on the molecular phenotype of the human Fallopian tube - Nature Communications The human Fallopian tube (FT) is implicated as a site of origin for pelvic serous cancers. Here the authors conduct multi-omics analysis on over 100 FTs. The results challenge the assumption that BRCA...

Surprising findings of BRCA mutations on the Fallopian tubes. Result of a tremendous team effort with @shenhui1986.bsky.social @vainstitute.bsky.social, Chuck Drescher @fredhutch.bsky.social, and Jarrod Marto @danafarber.bsky.social.
@pennmedcso.bsky.social
www.nature.com/articles/s41...